» Articles » PMID: 29904153

Mouse Models of Hepatocellular Carcinoma: an Overview and Highlights for Immunotherapy Research

Overview
Specialty Gastroenterology
Date 2018 Jun 16
PMID 29904153
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Mouse models are the basis of preclinical and translational research in hepatocellular carcinoma (HCC). Multiple methods exist to induce tumour formation in mice, including genetically engineered mouse models, chemotoxic agents, intrahepatic or intrasplenic injection of tumour cells and xenograft approaches. Additionally, as HCC generally develops in the context of diseased liver, methods exist to induce liver disease in mice to mimic viral hepatitis, fatty liver disease, fibrosis, alcohol-induced liver disease and cholestasis. Similar to HCC in humans, response to therapy in mouse models is monitored with imaging modalities such as CT or MRI, as well as additional techniques involving bioluminescence. As immunotherapy is increasingly applied to HCC, mouse models for these approaches are required for preclinical data. In studying cancer immunotherapy, it is important to consider aspects of antitumour immune responses and to produce a model that mimics the complexity of the immune system. This Review provides an overview of the different mouse models of HCC, presenting techniques to prepare an HCC mouse model and discussing different approaches to help researchers choose an appropriate model for a specific hypothesis. Specific aspects of immunotherapy research in HCC and the applied mouse models in this field are also highlighted.

Citing Articles

Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts.

Weinfurtner K, Tischfield D, McClung G, Crainic J, Gordan J, Jiao J JHEP Rep. 2025; 7(3):101264.

PMID: 40028346 PMC: 11869099. DOI: 10.1016/j.jhepr.2024.101264.


Liver sinusoidal endothelial cells regulate the balance between hepatic immunosuppression and immunosurveillance.

Kremer K, Khammash H, Miranda A, Rutt L, Twardy S, Anton P Front Immunol. 2025; 15:1497788.

PMID: 39896805 PMC: 11782242. DOI: 10.3389/fimmu.2024.1497788.


pir-hsa-216911 inhibit pyroptosis in hepatocellular carcinoma by suppressing TLR4 initiated GSDMD activation.

Liao Z, Yang L, Cheng X, Huang X, Zhang Q, Wen D Cell Death Discov. 2025; 11(1):11.

PMID: 39824843 PMC: 11742400. DOI: 10.1038/s41420-024-02285-9.


Precision models in hepatocellular carcinoma.

Barcena-Varela M, Monga S, Lujambio A Nat Rev Gastroenterol Hepatol. 2024; 22(3):191-205.

PMID: 39663463 DOI: 10.1038/s41575-024-01024-w.


AAV-mediated combination gene therapy of inducible Caspase 9 and miR-199a-5p is therapeutic in hepatocellular carcinoma.

Pathak S, Singh V, Kumar G N, Jayandharan G Cancer Gene Ther. 2024; 31(12):1796-1803.

PMID: 39385010 DOI: 10.1038/s41417-024-00844-x.